Indeed, previous studies showed the synergistic antitumoral effects of a combination of CDK4/6 inhibitors and MEK inhibitors in neuroblastoma [23], colorectal cancer [24,25], non-small cell lung cancer [26], and melanoma [27,28]. Here, CDK4 is linked to neuroblastoma.